Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Pancreatic Neoplasms 1Neoplasm Metastasis 1Lymphoma, Mantle-Cell 1Lymphoma 1Gastro-enteropancreatic neuroendocrine tumor 1Carcinoma, Islet Cell 1

Interventions

lutetium Lu 177 dotatate 2pembrolizumab 1pasireotide 1lanreotide 1folfirinox 1copper dotatate CU-64 1arginyllysine 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1Octreotide 1Nivolumab 1Lutetium-177 1Lutetium 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Cytokines 1Cryotherapy 1Carboplatin 1Acupuncture Therapy 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Gastro-enteropancreatic neuroendocrine tumor × Cytokines × Clear all
NCT03042780 2020-11-27

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Terminated
2 enrolled 6 charts
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor, Neoplasm Metastasis, Pancreatic Neoplasms, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡